Healthpeak Properties, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DOC research report →
Range $20 – $24
Price Chart
About the company
Healthpeak Properties, Inc. is an S&P 500 constituent operating as a fully integrated real estate investment trust (REIT). The firm is dedicated to the acquisition, management, and development of premier properties essential for both medical research and the provision of healthcare services.
- CEO
- Scott Brinker
- IPO
- 1985
- Employees
- 411
- HQ
- Denver, CO, US
Get TickerSpark's AI analysis on DOC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.27B
- P/E
- 35.54
- Fwd P/E
- 45.38
- PEG
- 0.02
- P/S
- 4.32
- P/B
- 1.68
- EV/EBITDA
- 12.70
- Div Yield
- 6.36%
- Gross Margin
- 3.34%
- Op Margin
- 16.22%
- Net Margin
- 12.66%
- ROE
- 5.00%
- ROIC
- 2.38%
Latest fiscal year · YoY change
- Revenue
- $2.82B+4.5%
- Gross Profit
- $634.55M-61.0%
- Op Income
- $544.13M
- Net Income
- $71.35M-70.7%
- EPS
- $0.10-72.2%
- OCF Growth
- +17.0%
- FCF Growth
- +17.0%
- 52W High
- $22.95
- 52W Low
- $15.70
- 50D MA
- $19.60
- 200D MA
- $19.30
- Beta
- 0.99
- RSI (14)
- 43
- Avg Volume
- 5.65M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Healthpeak raised 2026 guidance again as outpatient medical, life science leasing, and Janus Living all outperformed, while management said the portfolio is positioned for better 2027 occupancy and NOI growth.· November 3, 2026
- FFO as adjusted was $0.44 per share, same-store cash NOI grew 3.6%, and net debt to adjusted EBITDA was 4.7x.
- Management raised full-year FFO as adjusted guidance by $0.02 at the midpoint to $1.76-$1.78 per share, with same-store guidance lifted to 0.5%-2.0%.
- Outpatient medical executed 846,000 sq ft of leases in the quarter, posted 81.7% retention, and ended at 90.3% occupancy.
- Life science occupancy rose 130 basis points sequentially to 79.8%, with 480,000 sq ft of leases executed in the quarter and another 643,000 sq ft subsequent to quarter end in executions/LOIs.
- Senior housing was a major contributor, with Janus Living delivering 26% same-store NOI growth, 78% revenue growth, and 101% adjusted EBITDAre growth in the quarter.
Healthpeak reported FFO as adjusted of $0.44 per share, total same-store cash NOI growth of 3.6%, and net debt to adjusted EBITDA of 4.7x. Outpatient medical executed 846,000 sq ft of leases, with 81.7% tenant retention and cash releasing spreads of approximately 5% above historical averages; total occupancy ended at 90.3%. In life science, the company executed 480,000 sq ft of leases, and total occupancy increased 130 basis points sequentially to 79.8%. In senior housing, Janus Living delivered same-store NOI growth of 26%, total revenue growth of 78%, and adjusted EBITDAre growth of 101%. Management raised 2026 FFO as adjusted guidance to $1.76-$1.78 per share and lifted total same-store guidance to 0.5%-2.0%, including outpatient medical at 2.5%-3%, lab at down 3% to down 6%, and senior housing at 16%-19%.
Scott Brinker said the quarter validated the strategy across all three businesses and emphasized that the company increased guidance for the third time this year. He framed outpatient as benefiting from secular demand and said life science is showing improving supply-demand conditions, with Healthpeak using its local scale, tenant relationships, and balance sheet to buy and lease up strategic assets. His tone was confident and assertive, repeatedly stressing that the company is becoming the leading platform in outpatient and life science and that Janus is helping drive external growth in senior housing.
Kelvin Moses focused on operating execution, stating that each segment is running ahead of plan and giving the key financial metrics: FFO as adjusted of $0.44 per share, same-store cash NOI growth of 3.6%, and net debt to adjusted EBITDA of 4.7x. He also highlighted liquidity of approximately $3.8 billion as of October 30 and described the balance sheet actions, including two delayed draw term loans priced at SOFR +80 basis points, one $400 million facility expected to be drawn in the fourth quarter and a $500 million facility expected in the first quarter of 2027. He said the company has about $1.4 billion of 2027 maturities and expects CapEx to stay roughly consistent with recent years rather than rise dramatically.
Analysts pressed on the life science acquisition strategy, including why Healthpeak is adding vacancy exposure and how far along lease-up conversations are; management said it is underwriting the acquisitions to fully lease up in the two-to-three-year range and that about 70% of the acquired vacancy is in active negotiations. Questions also focused on 2027 earnings growth, debt maturities, and the pace of NOI from signed leases; management said lease executions generally take 12-15 months to flow into NOI and earnings because of build-out and free-rent periods. On the market backdrop, management said rate volatility could slow transactions and that life science demand is increasingly coming from biotech plus AI/robotics users, while the credit profile of lab tenants has improved.
The call showed broad operational momentum: guidance was raised again, outpatient occupancy and leasing remain healthy, life science occupancy has improved materially, and senior housing is producing strong growth. Management also argued that Healthpeak is finding rare opportunities to buy strategic life science assets at low bases with meaningful upside, supported by its local footprint and leasing capabilities.
The biggest risk discussed was timing: life science leases can take 12-15 months to translate into NOI, so near-term earnings growth may lag occupancy gains. Management also flagged higher refinancing costs, $1.4 billion of 2027 maturities, and a potentially slower transaction market if rate volatility persists, which could pressure valuations and earnings in the near term.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.6%
- Shares Outstanding
- 689.54M
- Float Shares
- 686.73M
of shares held by institutions
781 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for DOC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jan 9, 26 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Aug 4, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 17, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | May 15, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Apr 1, 25 | Filing → |
| Chris JacobsHouse · NY27 | Buy | Dec 12, 22 | Filing → |
| Chris JacobsHouse · NY27 | Sell | Nov 8, 22 | Filing → |
| Chris JacobsHouse · NY27 | Sell | Jul 18, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 109.04M | ▼ 311.87K |
| Blackrock, Inc. | 83.75M | ▲ 12.81M |
| Vanguard Portfolio Management LLC | 57.80M | ▼ 574.88K |
| Vanguard Capital Management LLC | 45.18M | ▲ 167.80K |
| State Street Corp | 44.42M | ▲ 410.47K |
| Geode Capital Management, LLC | 25.78M | ▲ 1.12M |
| Jpmorgan Chase & Co | 23.68M | ▼ 6.51M |
| Invesco Ltd. | 21.50M | ▲ 3.00M |
| Fuller & Thaler Asset Management, Inc. | 20.83M | ▼ 8.29M |
| Bank Of New York Mellon Corp | 18.19M | ▲ 2.96M |
| Principal Financial Group Inc | 14.82M | ▼ 1.94M |
| Fmr LLC | 12.39M | ▲ 1.88M |
Held by 972 ETFs
Biggest fund positions in DOC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Thomas John T | other | 12,350 |
| Nov 9, 26 | Patadia Ankit B. | sell | 6,115 |
| Nov 5, 26 | Lewis Sara Grootwassink | other | 46,744 |
| Nov 5, 26 | Lewis Sara Grootwassink | other | 46,744 |
| May 29, 26 | Thomas John T | other | 1,385 |
| May 29, 26 | Thomas John T | other | 78 |
| May 29, 26 | Patadia Ankit B. | other | 1,358 |
| May 29, 26 | Patadia Ankit B. | other | 94 |
| May 29, 26 | Moses Kelvin O | other | 937 |
| May 29, 26 | Moses Kelvin O | other | 65 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DOC coverage
Recent articles, reports, and earnings notes.

Healthpeak Properties (DOC): Outpatient Growth and Senior Housing Turnaround
Healthpeak Properties is showing improving operating momentum across outpatient medical, life science, and senior housing, but valuation remains demanding. The Buy case is supported by stronger same-store NOI, rising occupancy, and a higher full-year FFO outlook.

Healthpeak Properties, Inc. (DOC) gains on deep earnings analysis
Healthpeak Properties, Inc. (DOC) gained despite an earnings miss, as revenue beat estimates and operating trends improved across senior housing, lab, and outpatient medical assets. This deep-dive analysis looks beyond the headline to assess occupancy gains, leasing momentum, raised FFO guidance, and what the mixed print means for DOC shares.

Healthpeak Properties, Inc. (DOC) gains on earnings misses
Healthpeak Properties, Inc. (DOC) gains 2.4% after reporting earnings misses, as investors weigh the latest results against the stock's recent momentum.
Want a deeper read on DOC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
The Roth IRA Mistake That Turns a 59-Year-Old’s $6,325 a Month in Tax-Free Dividends Into a Tax Bill
247wallst.com · Nov 20
3 Healthcare REITs Raised Their 2026 Outlooks as Senior Housing Demand Grows
247wallst.com · Nov 20
Buried Treasures: 6 Strong, Undervalued High-Yield REITs
seekingalpha.com · Nov 19
264,694 Healthpeak Properties, Inc. $DOC Shares Sold by Eurizon Capital SGR S.p.A.
defenseworld.net · Nov 19
Healthpeak Properties' Scavenger Mentality
seekingalpha.com · Nov 12
Doctors' Offices, Labs and Nursing Homes Pay Rent to These 3 REITs, and $150,000 Yields $8,510 a Year
247wallst.com · Nov 9
November Buy: 6 IDEAL S&P 500 'Safer' Dividend Dogs
seekingalpha.com · Nov 6
American Healthcare REIT (NYSE:AHR) versus Healthpeak Properties (NYSE:DOC) Head to Head Comparison
defenseworld.net · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.